Table V.
Expression of TfR and the proliferation marker Ki-67 in dog tumors according to immunohistochemistry.
| Case | Species | Breed | Weight, Sex | kg | Age, years | Percentage of TfR-positive cells | Percentage-of Ki-76 postive cells | Histology |
|---|---|---|---|---|---|---|---|---|
| 1 | Cat | European shorthair | Fcastr | 4 | 3 | 94.3±9.0 | 85.7±4.7 | Tubulopapillary breast adenocarcinoma |
| 2 | Dog | Mix | Fcastr | 17 | 13 | 95.1±3.6 | 84.8±5.9 | Tubulopapillary breast adenocarcinoma |
| 3 | Dog | Weimarian | M | 28 | 8 | 99.7±0.1 | 72.5±4.4 | Soft tissue sarcoma, Grade 1 |
| 4 | Dog | Deutsch-Adrahthaar | Fcastr | 28 | 9 | 87.2±9.6 | 71.6±9.7 | Tubulopapillary breast adenocarcinoma with lymph node metastasis |
| 5 | Dog | French bulldog | Mcastr | 11 | 7 | 83.9±6.8 | 53.5±18.7 | Soft tissue sarcoma, Grade 1 |
| 6 | Dog | American Staffordshire Terrier | Mcastr | 33 | 3 | 98.6±0.5 | 49.1±4.9 | Mastocytoma, Type 2 |
| 7 | Dog | Mix | M | 21 | 12 | 52.1±32.1 | 43.5±3.1 | Hemangiosarcoma |
| 8 | Dog | Podenco | Fcastr | 24 | 12 | 99.9±0.1 | 41.1±16.3 | Osteosarcoma |
| 9 | Dog | Blue lacy | M | 26 | 11 | 99.8±0.2 | 33.9±5.0 | Mastocytoma, Type 2 |
| 10 | Dog | Mix | F | 14 | 2 | 43.5±37.9 | 33.2±13.8 | Mastocytoma, Type 2 |
| 11 | Cat | European shorthair | Fcastr | 4 | 5 | 97.4±1.8 | 31.3±8.3 | Neuroendocrine carcinoma |
| 12 | Dog | Podenco | Fcastr | 25 | 12 | 84.6±9.5 | 30.5±10.7 | Osteosarcoma, highly malignant |
| 13 | Dog | Rottweiler | Fcastr | 51 | 8 | 99.0±0.1 | 30.1±14.6 | Adenocarcinoma metastasis |
| 14 | Dog | Mix | Mcastr | 27 | 10 | 99.1±1.4 | 29.5±8.4 | Teleangiectatic osteosarcoma |
| 15 | Dog | Labrador mix | F | 37 | 12 | 95.2±3.9 | 28.6±7.4 | Carcinoma |
| 16 | Dog | Labrador | M | 43 | 9 | 99.2±0.6 | 21.3±9.7 | Squamous cell carcinoma |
| 17 | Dog | Podenco | Fcastr | 24 | 12 | 53.3±17.8 | 6.6±1.8 | Breast carcinoma, complex/myxoid |
Data are present as the mean ± standard deviation. F, female; M, male; castr, castrate; TfR, transferrin receptor.